updated 2/15/2011 7:16:11 AM ET 2011-02-15T12:16:11

CHATSWORTH, Calif., Feb. 15, 2011 (GLOBE NEWSWIRE) -- IRIS International, Inc. (Nasdaq:IRIS), will release its 2010 fourth quarter and year-end financial results after the close of trading on Monday, February 28, 2011.   IRIS management will also host a conference call and webcast that day at 4:30 P.M. Eastern Time, to discuss the financial results, as well as provide a general business update:

Date:   Monday, February 28, 2011
Time:   4:30 PM ET

To listen via live webcast, please go to the IRIS website (10 min. before conference is scheduled to begin) at: http://www.proiris.com/investors/Webcasts_and_Presentations.php

To participate in the teleconference, please dial (10 min. before conference is scheduled to begin):

Domestic toll-free:   1 - 877- 870 - 9220
International:  +  973 - 638 - 3437

If you are unable to participate during the live conference call and webcast, the conference call audio cast will be archived and available for replay in the Investors section of the Company's website at http://www.proiris.com for approximately 90 days.

About IRIS International, Inc.

IRIS International, Inc. is a leading global in vitro diagnostics company focused on products that analyze particles and living cell forms and structures, or morphology of a variety of body fluids. The Company's products leverage its strengths in flow imaging technology, particle recognition and automation to bring efficiency to hospital and commercial laboratories. The initial applications for its technology have been in the urinalysis market and the Company is the leading worldwide provider of automated urine microscopy and chemistry systems, with an installed base of more than 3,000 systems in more than 50 countries. The Company is expanding its core imaging and morphology expertise into related markets and is developing applications in hematology and urinary tract infections. In addition, the Company recently acquired a high complexity CLIA-certified molecular pathology laboratory offering differentiated, high value molecular diagnostic services in the rapidly growing field of personalized medicine. The laboratory provides a direct commercial channel for the Company's NADiA® ultra-sensitive nucleic acid detection immunoassay platform, with applications in oncology and infectious disease. For more information, please visit www.proiris.com .

CONTACT: Cesar Garcia
         Chairman, President and Chief Executive Officer
         IRIS International, Inc.
         Ron Stabiner, The Wall Street Group, Inc.

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved


Discussion comments


Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 3.79%
$30K home equity loan FICO 4.99%
$75K home equity loan FICO 4.69%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.83%
Cash Back Cards 17.80%
Rewards Cards 17.18%
Source: Bankrate.com